Results 81 to 90 of about 2,329 (147)

Exploring SK/S1P/S1PR pathway as a target for antiviral drug development

Health Sciences Review
Lysophospholipids are a class of simple phospholipids that shows their biological effects through various G protein-coupled receptors (GPCRs). Sphingosine 1-phosphate (S1P) is one of the most studied lysophospholipid having wide role in various ...
Sharada Prasanna Swain, Chandra Sekhara Mahanta, Madan Maurya, Debabrata Mandal, Vipan Parihar, V. Ravichandiran   +5 more
doaj   +1 more source

Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons

Journal of Comparative Effectiveness Research
Aim: Diroximel fumarate (DRF), ozanimod (OZA) and interferon beta-1a (IFN) are disease-modifying therapies approved for the treatment of relapsing multiple sclerosis. No randomized trials have compared DRF versus OZA and IFN. We compared DRF versus OZA
Tammy Jiang, Mathura Shanmugasundaram, Ivan Bozin, Mark S Freedman, James B Lewin   +4 more
doaj   +1 more source

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

, 2019
BACKGROUND Ozanimod is a sphingosine 1-phosphate receptor modulator, which selectively binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity.
Arnold DL, Sheffield JK, Steinman L, Hartung HP, Comi G, Bar-Or A, Cohen JA, Raghupathi K, Kubala Havrdová E, Huang V, Kappos L, Montalban X, Minton N, Cree BAC, Selmaj KW   +14 more
core   +1 more source

Unique pharmacological properties of etrasimod among S1P receptor modulators

FEBS Open Bio
Etrasimod (ADP334) is an oral, once‐daily, selective sphingosine 1‐phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis and in development for the treatment of immune‐mediated inflammatory diseases.
Ibragim Gaidarov, H. Kiyomi Komori, Dariusz T. Stepniak, Karin Bruinsma, Huong Dang, Xiaohua Chen, Todd Anthony, Joel Gatlin, Lisa Karimi‐Naser, Anh‐Tuan Ton, Tim Indersmitten, Paul E. Miller, Andre Ghetti, Najah Abi‐Gerges, David Unett, Hussien Al‐Shamma, Christopher J. Rabbat, Catherine Crosby, John W. Adams   +18 more
doaj   +1 more source

Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial. [PDF]

BACKGROUND: Monoamine oxidase (MAO) inhibitors can interact with selective serotonin reuptake inhibitors (SSRIs)/serotonin-norepinephrine reuptake inhibitors (SNRIs).
Cheng, Chun-Yen, Cree, Bruce Ac, Bar-Or, Amit, Naismith, Robert, Sheffield, James K, Silva, Diego, Tatosian, Daniel, Selmaj, Krzysztof, Cree, Bruce, Comi, Giancarlo, Selmaj, Krzysztof W, Riolo, Jon V, Sheffield, James, Khaychuk, Vadim, Krakovich, Anthony, Riolo, Jon, Hartung, Hans-Peter, Reardon, Jennifer, Cohen, Jeffrey, Naismith, Robert T, Cohen, Jeffrey A   +20 more
core   +1 more source

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.

, 2021
BACKGROUND: Patients with multiple sclerosis (MS) experience relapses and sustained disability progression. Since 2004, the number of disease-modifying therapies (DMTs) for MS has grown substantially.
Kumar, Jinender, Tencer, Tom, Cohan, Stanley, Zhu, Xuelian, Arndorfer, Stella, Zivkovic, Marko   +5 more
core  

Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis [PDF]

Background: Ozanimod, approved for the treatment of moderately to severely active ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), is a weak in vitro monoamine oxidase B (MAO-B) inhibitor.
Horst, Sara, Wu, Hsiuanlin, Petersen, AnnKatrin, Regueiro, Miguel, Lawlor, Garrett, Siegmund, Britta, Moslin, Ryan, Fischer, Monika, D’Haens, Geert, Charles, Lorna, Tatosian, Daniel, Colombel, Jean-Frederic   +11 more
core   +1 more source

S1PR4-dependent effects of Etrasimod on primary human myeloid immune cell activation

Frontiers in Pharmacology
BackgroundSphingosine-1-phosphate (S1P) and its five receptors S1PR1-5 play an essential role in the migration, differentiation and activation of various immune cells.
Fiona K. Sailer, Megan A. Palmer, Blerina Aliraj, Jan Heering, Jan Heering, Andreas Brockmann, Mohammed A. F. Elewa, Mohammed A. F. Elewa, Aissa Röhrig, Aissa Röhrig, Ewgenij Proschak, Ewgenij Proschak, Ewgenij Proschak, Dariusz T. Stepniak, Simeon Ramsey, Bernhard Brüne, Bernhard Brüne, Andreas Weigert   +17 more
doaj   +1 more source

Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's Disease

BACKGROUND: Ozanimod showed efficacy and safety in the phase 2 STEPSTONE study conducted in patients with moderately to severely active Crohn's disease.
Ghosh, Subrata, Yan, Jim, Hanauer, Stephen, Vermeire, Severine, Feagan, Brian G., Wu, Chun, D’Haens, Geert, D'Haens, Geert, Wolf, Douglas C, Harris, Sarah, Maddux, Rachel, Feagan, Brian G, Wolf, Douglas C., Hu, Yanhua   +13 more
core   +1 more source

A Review of the Current State of Off‐Label Therapies for Pediatric Inflammatory Bowel Disease

Pediatric Discovery
Off‐label use of biologic therapies in patients with pediatric inflammatory bowel disease (IBD) has seen an increase in utilization. In this paper, we review the current state of off‐label therapies in the pediatric IBD population.
Yassin EL‐Najjar, Mary‐Joe Touma, Shuai Tan, Xiaoqin Zhou, Qi Liu   +4 more
doaj   +1 more source